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Abstract
Background: HIV patients are at increased risk of development of infections and infection-associated poor health
outcomes. We aimed to 1) assess the prevalence of USA300 community-associated methicillin-resistant
Staphylococcus aureus (CA-MRSA) among HIV-infected patients with S. aureus bloodstream infections and. 2)
determine risk factors for infective endocarditis and in-hospital mortality among patients in this population.
Methods: All adult HIV-infected patients with documented S. aureus bacteremia admitted to the University of
Maryland Medical Center between January 1, 2003 and December 31, 2005 were included. CA-MRSA was defined
as a USA300 MRSA isolate with the MBQBLO spa-type motif and positive for both the arginine catabolic mobile
element and Panton-Valentin Leukocidin. Risk factors for S. aureus-associated infective endocarditis and mortality
were determined using logistic regression to calculate odds ratios (OR) and 95% confidence intervals (CI). Potential
risk factors included demographic variables, comorbid illnesses, and intravenous drug use.
Results: Among 131 episodes of S. aureus bacteremia, 85 (66%) were MRSA of which 47 (54%) were CA-MRSA.
Sixty-three patients (48%) developed endocarditis and 10 patients (8%) died in the hospital on the index admission
Patients with CA-MRSA were significantly more likely to develop endocarditis (OR = 2.73, 95% CI = 1.30, 5.71). No
other variables including comorbid conditions, current receipt of antiretroviral therapy, pre-culture severity of
illness, or CD4 count were significantly associated with endocarditis and none were associated with in-hospital
mortality.
Conclusions: CA-MRSA was significantly associated with an increased incidence of endocarditis in this cohort of
HIV patients with MRSA bacteremia. In populations such as these, in which the prevalence of intravenous drug use
and probability of endocarditis are both high, efforts must be made for early detection, which may improve
treatment outcomes.
Background
Staphylococcus aureus bacteremia is a serious health
condition associated with considerable morbidity and
mortality among infected patients [1]. Negative out-
comes associated with S. aureus bacteremia include pro-
longed hospital stay, endocarditis, sepsis, and death
[1,2]. The changing epidemiology of S. aureus, including
the increasing incidence and prevalence of methicillin-
resistant S. aureus (MRSA) and the emergence of com-
munity-associated MRSA (CA-MRSA) further challenges
clinicians when treating S. aureus bacteremia. A recent
meta-analysis suggested that patients with MRSA bac-
teremia are at increased risk of death, and a longer post
infection hospital length of stay compared to patients
with bacteremia due to methicillin-susceptible S. aureus
[1]. Furthermore, increasing evidence suggests that
transmission of CA-MRSA is becoming more prevalent
in healthcare settings and an emerging epidemic
throughout the HIV community [3,4]. * Correspondence: forrestg@ohsu.edu
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patients places them at increased risk of infection
including S. aureus bacteremia and associated poor out-
comes [3,5,6]. Studies suggest that HIV patients are also
at increased risk of CA-MRSA infections from overlap-
ping community networks as well as the high prevalence
of intravenous drug use in some areas [7,8]. Indepen-
dent factors described as risks for MRSA bacteremia
within HIV-infected patients have been intravenous
drug use, hemodialysis and CD4 counts < 200 [9] while
clinical outcomes suggest that incidence of re-infection
and one-year mortality are high [3]. Recent data from a
study by Kempker et al. suggested that CA-MRSA bac-
teremia was associated with advanced age, black race
and AIDS infection as well as increased mortality com-
pared to other strains [10]. However, despite this recent
work, outcomes for CA-MRSA bacteremia and endocar-
ditis among HIV patients have not been well-described.
I nt h i ss t u d yw ea i m e dt o1 )a s s e s st h ep r e v a l e n c eo f
USA300 community-associated methicillin-resistant Sta-
phylococcus aureus (CA-MRSA) among HIV-infected
patients with S. aureus bloodstream infections and 2)
determine risk factors for infective endocarditis and in-
hospital mortality among patients in this population.
Methods
Study Population
Prior to study commencement, the University of Mary-
land, Baltimore Institutional Review Board approved this
study. This was a retrospective cohort study of all adult
(age ≥18) HIV-infected patients with MRSA bacteremia
admitted to the University of Maryland Medical Center
(UMMC) between January 1, 2003 and December 31,
2005. During the study period, UMMC was a 648-bed,
tertiary-care facility in Baltimore, MD, which included a
40-bed in-patient HIV service. Baltimore has the fifth
highest incidence case report rate of people living with
HIV/AIDS of any major metropolitan area in the U.S.
with 2037.8 cases/100,000 population as of 2007and a
high incidence of CA-MRSA at approximately 119
cases/100,000 population [11,12]. Data on rates of
MRSA infection admitted to UMMC within this time
period of being consistently around 50% have previously
been published [13].
Patients with MRSA bacteremia for the time period
evaluated were identified through Premier Safety Sur-
veillor
® (Premier, Inc., Charlotte, N.C), an automated
epidemiological surveillance program used by UMMC
for infection control purposes and from which work has
previously been described [14,15]. Duplicate cultures
f r o mt h es a m ea d m i s s i o nw e r et h e nr e m o v e da n dH I V
status was then cross-referenced with the central data
repository. The central data repository has been used in
numerous epidemiologic studies of antimicrobial-
resistant bacteria published in the peer-reviewed jour-
nals [16-18]. The flow diagram shows how the final
patient population was determined. (Figure 1)
Data Collection
Patient data were retrospectively collected via review of
patient medical charts and through a central data repo-
sitory of patients’ administrative, pharmaceutical, and
laboratory data. Chart review was performed by a clini-
cian using a standardized data abstraction form. Data
collected included past and current medical history:
demographics, comorbid conditions, and clinical presen-
tation on admission and just prior to positive blood cul-
ture. Clinical presentation included CD4 count (cells/
mm
3), and whether the patient was receiving effective
antiretroviral therapy (ART) of at least 3 active agents.
In addition, data on HIV viral load were collected if
available within 6 weeks (on either side) of the
admission.
Figure 1 Selection of HIV-infected patients with methicillin
resistant Staphylococcus aureus bacteremia flowsheet.
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AIDS was defined as a CD4 < 200 cells/mm
3 or current
opportunistic infection, Hepatitis C infection was
defined as having documented serologic positivity, dia-
betes mellitus was defined as receiving insulin or oral
hypoglycemic medication, hypertension was any patient
receiving antihypertensive therapy, coronary artery dis-
ease was defined as any prior myocardial infarction,
interventional procedure or bypass surgery. Illicit sub-
stance use (ISU) was determined by history and when
possible toxicology screen results. End stage renal dis-
ease was defined as per National Kidney Foundation
guidelines as stage 4 or 5 kidney disease including the
need for renal replacement therapy [19]. Severity of ill-
ness was defined using the Acute Physiology and
Chronic Health Evaluation (APACHE) II score at the
time of initial positive blood culture collection. Endocar-
ditis was diagnosed using either transesophageal (TEE)
or transthoracic echocardiography (TTE) and defined
according to the modified Duke criteria, with allocation
to left-sided, right-sided, or bilateral disease [20]. Mor-
tality was defined as in-hospital mortality on the index
admission.
Laboratory Methods
Blood cultures were drawn as per standard hospital pol-
icy from two separate sites and collected in blood cul-
ture bottles (BacTAlert, bioMerieux, Durham, NC).
Cultures were placed in a continuous automated detec-
tion incubator. Positive blood culture bottles were plated
onto standard growth media as per standard laboratory
protocol and susceptibilities were performed using disk
diffusion following the Clinical and Laboratory Stan-
dards Institute (CLSI) guidelines [21,22]. The first S.
aureus positive blood culture per patient per admission
was included in the analysis. Thus, patients could have
contributed more than one episode of S. aureus bactere-
mia to the data, so long as the cultures occurred on dif-
ferent inpatient admissions and were not treated for
endocarditis in last 90 days.
MRSA spa-type was determined using the methods
proposed by Shopsin et al. and Harmsen et al [23,24].
Presence of Panton-Valentine leukocidin (PVL) and
arginine catabolic mobile element (ACME) was deter-
mined using the previously described protocols [25,26].
CA-MRSA was defined as a USA300 MRSA isolate with
the MBQBLO spa-type motif that was both PVL and
ACME positive as has been previously described
[25,27,28]. This method was validated by performing
pulsed-field gel electrophoresis on isolates that met two
of the three following criteria: MBQBLO spa-type motif,
PVL positive, ACME positive. Of those that met two of
the three criteria, none were USA300. Although there
are other CA-MRSA strains, USA300 MRSA is the
predominant strain type associated with CA-MRSA
colonization and infection [29].
Statistical analysis
Student’s t-tests, chi-square, Fisher’s exact, and Wil-
coxon rank sum tests were used to identify differences
between patients with an without CA-MRSA and
between those who and did and did not develop endo-
carditis or die on the index admission. All variables that
were statistically significant (a =0 . 1 )i nt h eb i v a r i a b l e
analyses were included in the initial (full) multivariable
logistic regression model. In each of the multivariable
analyses performed, variables not significantly associated
(a = 0.05) with the outcome were removed from the
model. Each of the removed variables was then re-
inserted into the model to assess if its presence altered
the regression coefficient by 20% or more. If so, this
confounding variable was included in the final model.
T h er e s u l t i n gm u l t i v a r i a b l el o g i s t i cr e g r e s s i o nm o d e l
was considered the final model and was used to calcu-
late odds ratios (ORs) and 95% confidence intervals (CI)
for the remaining risk factors. All analyses were con-
ducted using SAS statistical software, Version 9.1.2 (SAS
Institute, Cary, NC).
Results
We identified 131 individual episodes of S. aureus bac-
teremia among HIV-positive patients during the study
period. All episodes occurred within 72 hours of admis-
sion. Characteristics of the study population are dis-
played in Table 1.Twenty one percent of the patients
had a diagnosis of AIDS. The mean CD4 count of the
cohort was 126 cells/per mm
3 (standard deviation =133
cells/per mm
3) and median CD4 count was 56 cells/per
mm
3 (interquartile range [IQR] 16-169 cells/per mm
3).
The mean HIV viral load was 225,000 copies/ml and
only 15 patients having a suppressed HIV viral load in
this cohort. Of note, prevalence of co-infection with
hepatitis C virus was 63%, prevalence of ISU was 50%,
and 30% of patients were receiving ART. Approximately
66% (n = 87) of S. aureus isolates were MRSA of which
47 (54%) were CA-MRSA. Antibiotic susceptibilities and
molecular characteristics of the S. aureus isolates are
displayed in Table 2. Initial empiric antibiotic selection
for the treatment of CA-MRSA bacteremia would not
be effective therapy in 27 of the patients (31%).
The prevalence of endocarditis was approximately 48%
and in-hospital mortality during the index admission
was approximately 8%. Among the 63 patients with
endocarditis, 51 (81%) had right-sided endocarditis only.
Of the 31 MRSA patients (35%) that had both a TEE
and TTE, 5 vegetations (2 aortic, 2 mitral, 1 pulmonic)
were detected by TEE that were not seen by TTE, but
this was not related to whether they had CA or Non-
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common with septic pulmonary emboli occurring in 11
of the CA-MRSA patients and 6 non-CA-MRSA
patients (p = 0.32). However, there were significantly
more deep abscesses in the CA-MRSA group compared
to the non-CA-MRSA group (17 versus 1 p < 0.001). Of
the 17 CA-MRSA patients with deep abscesses, 7
patients had lung abscess or empyema, 5 patients had
pyomyositis (psoas and spinal muscle abscesses), 2
patients had renal abscesses, 2 patients had a brain
abscess and one patient had a pericardial empyema. The
non-CA-MRSA group deep abscesses had one epidural
abscess. The mean duration of bacteremia was not sig-
nificantly different between the patients with CA-MRSA
(mean 1.85 days) and those with non-CA-MRSA (1.45
days) p = 0.43).
Table 3 displays the unadjusted odds ratios for the
association between different variables and endocarditis.
Patients with CA-MRSA infections had nearly three
times the odds of endocarditis and this association was
statistically significant (OR = 2.73, 95% CI = 1.30, 5.71).
No other variables were significantly associated with
endocarditis in the bivariate analyses. Logistic regression
was use to perform multivariable analyses, but no other
variables were significantly associated with endocarditis.
No variables were significantly associated with in-hospi-
tal mortality. CA-MRSA was associated with nearly
three times the odds of in-hospital mortality, (OR =
2.93, 95% CI = 0.78, 10.96). We could not fully evaluate
the associations between APACHE ≥ 11 and receiving
ART and mortality, because none of the patients who
received ART died and none of the patients with
APACHE less than 11 died.
Discussion
We present the largest cohort of HIV patients with CA-
MRSA bacteremia and endocarditis documented to date.
T h e s ed a t as u g g e s tah i g hp r e v a l e n c eo fC A - M R S A
among HIV patients presenting with S. aureus bactere-
mia at our institution and that CA-MRSA was signifi-
cantly associated with the development of endocarditis
compared to non-CA-MRSA. Furthermore, although not
significant, patients with CA-MRSA also appeared to be
at increased risk of death compared to patients with
other S. aureus bloodstream infections.
Table 1 Characteristics of the Patients with
Staphylococcus aureus bacteremia (n = 131)
Characteristic n (%)
Mean (SD) Age, (years) 41.5 (7.5)
Male Sex 83 (63.4)
African American 119 (91)
Receiving ART 39 (29.8)
Mean (SD) APACHE Score 12.1 (5.3)
CD4 <200 cells/mm
3 28 (21.4)
Hepatitis C 82 (62.6)
Diabetes Mellitus 3 (2.3)
Coronary Artery Disease 0 (-)
Hypertension 13 (9.9)
Intravenous Drug Use 66 (50.4)
End-stage Renal Disease 24 (18.3)
Median (IQR) Length of Stay (days) 7 (5, 14)
Endocarditis 63 (48.1)
Right-sided only 51 (38.9)
Left-sided only 8 (6.1)
Bilateral 4 (3.1)
In-hospital Mortality 10 (7.6)
Note: ART: Antiretroviral therapy, SD: standard deviation, IQR: interquartile
range, APACHE: Acute Physiology and Chronic Health Evaluation score.
Table 2 Characteristics of the Staphylococcus aureus
isolates (n = 131)
Characteristic n (%)
Antibiotic Susceptibilities
Methicillin Resistant 87 (66)
Clindamycin Resistant 25 (19.1)
Trimethoprim-Sulfamethoxazole Resistant 42 (32.1)
Molecular Characteristics*
Panton Valentine Leukocidin (PVL)* 53 (61.6)
Arginine Catabolic Mobile Element (ACME)* 50 (58.1)
USA300 MRSA* 47 (54.0)
*Proportion is only among MRSA isolates
Table 3 Odds Ratios (ORs) and 95% Confidence Intervals
(CIs) for Associations of various Risk Factors for
Endocarditis and In-hospital Mortality among HIV
Patients with Staphylococcus aureus Bacteremia (n = 131)
Endocarditis In-hospital Mortality
Characteristic OR (95% CI) OR (95% CI)
CA-MRSA 2.73 (1.30, 5.71) 2.93 (0.78, 10.96)
Age 0.98 (0.94, 1.03) 1.08 (0.99, 1.17)
Male Sex 0.46 (0.22, 0.94) 0.35 (0.10, 1.33)
Receiving ART 0.67 (0.31, 1.42) *
APACHE II ≥11 1.71 (0.85, 3.42) **
CD4 <200 cells/mm
3 2.01 (0.87, 4.62) 0.47 (0.08, 2.91)
Hepatitis C 1.23 (0.60, 2.50) 0.57 (0.16, 2.08)
Hypertension 0.92 (0.40, 2.12) 0.91 (0.18, 4.57)
Intravenous Drug Use 1.79 (0.90, 3.59) 1.58 (0.42, 5.87)
End-stage Renal Disease 1.23 (0.48, 3.12) 0.56 (0.07, 4.68)
Note: CA-MRSA: community-associated methicillin-resistant Staphylococcus
aureus, ART: antiretroviral therapy, APACHE: Acute Physiology and Chronic
Health Evaluation score
*Could not be calculated because no patients receiving ART died.
**Could not be calculated because no patients with APACHE <11 died.
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bacteremia cases from eight hospitals over 3 years in the
Atlanta, GA metropolitan area.(10) They had 414 epi-
sodes of CA-MRSA bacteremia of which 63 (16.2%)
occurred in HIV positive patients and only 17 (4.1%)
were associated with endocarditis. They observed greater
in-hospital mortality (17%) compared to 8% in our
study, however similar to the patients in our cohort,
they observed more deep abscesses in their CA-MRSA
g r o u pc o m p a r e dt ot h en o n - C A - M R S Ag r o u p[ 1 0 ] .
Wang et al. performed a study of adult patients with S.
aureus bacteremia in Taiwan, however, only 3 (10%) of
their CA-MRSA bacteremia episodes had endocarditis,
and none were HIV positive. On their univariate analy-
sis, women appear to have a two-fold increase of dying
with CA-MRSA bacteremia, a similar finding to our
study [30]. Several other papers on CA-MRSA bactere-
mia have had very few cases of endocarditis most of
which appear to be associated with deep abscesses and
pulmonary disease [31-34]. Kreisel et al evaluated CA-
MRSA bacteremia and severe sepsis at 4 Veteran Affairs
(VA) centers, which includes the Baltimore VA medical
center and demonstrated that CA-MRSA was associated
with more severe sepsis (adjusted relative risk 1.82, con-
fidence intervals 1.16-2.87, p = 0.01) [35]. They also
noted that there was a greater propensity to ISU and
African American patients having these severe infec-
tions, which is consistent with our population [35,36].
Another major difference between our study and pre-
viously published work is the antibiotic susceptibility
profile of our CA-MRSA strains compared to other stu-
dies with high levels of trimethoprim-sulfamethoxazole
(TMP-STX) resistance, which was 32% of all isolates
and 48% of the CA-MRSA isolates. This compares to
ranges of 0-13% in other published studies [30,32-34].
TMP-STX resistance could have several possible expla-
nations given the patient population examined; 1) As
the majority of the patients had a history of intravenous
drug usage, it is possible they had more abscesses in the
past and had been treated with TMP-STX several times
or 2) the majority of the patients had CD4 < 200 cells/
mm
3 and were most likely taking TMP-STX for preven-
tion of pneumocystis pneumonia. The second explana-
tion appears more likely as our clindamycin resistance
was similar to other studies [30,32-34].
Our data compare similarly to data published from
Detroit, which also has high rates of CA-MRSA. CA-
MRSA was responsible for 35% of bloodstream infec-
tions in their series, but there were only 3% HIV
infected patients in their cohort [37]. Lalani et al. during
a multicenter clinical trial that the reported a prevalence
of CA-MRSA was 12% among 230 S. aureus isolates and
31% among the 88 typed MRSA isolates in a multicenter
clinical trial.(28) Incidence of endocarditis was 23%.
However, in contrast to our study, the Lalani et al.
study population had a low prevalence of HIV/AIDS of
approximately 3% and thus a thorough comparison to
the patients in our study is not possible. Gebo et al.
assessed risk factors and outcomes of 58 cases of infec-
tive endocarditis among HIV-infected patients and iden-
tified intravenous drug use, low (<50 cells/mm
3)C D 4
counts, and high (HIV RNA >100,000 copies/ML) viral
load as independent risk factors for endocarditis. (3)
Although S. aureus was the most prevalent organism
(69% of cases) in their study, only 28% of S. aureus iso-
lates were MRSA, which also complicates comparison to
our data, which focused on differences in risk factors
and outcomes between CA-MRSA and non-CA-MRSA.
We observed relatively low mortality (~8%) despite
that greater than 20% of patients had a CD4 count of
<200 cells/mm
3 and less than 30% were receiving ART.
The low rate of ART use in our population with high
ISU reflects the difficulty in obtaining compliance in
this population. There have been several studies on the
difficulties in getting the HIV infected ISU patients to
establish and maintain antiretroviral usage in the city of
Baltimore. It has been suggested that ISU infected
patients with HIV who were not receiving ART tended
to be active drug users without clinical disease [38]. It
may explain why there was higher mortality in women
in our study with the sex for illicit drug trade delaying
the presentation for care [39].
Our results contrast previous studies, which observed
mortality from 18% to 52% [3,5]. However, the associa-
tions between ISU, right-sided endocarditis and low
relative mortality have been previously described, even
among HIV patients [40]. Recall that more than 80% of
our patients with endocarditis had right-sided disease
only. Furthermore, as has been previously reported, the
criteria used to measure mortality often vary in studies
of infectious disease outcomes [41]. For example, the
52% mortality reported by Gebo et al. included all
deaths within one year, some of which were likely not
attributable to the endocarditis episode [3]. The low
mortality in this study relative to the potential serious-
ness of the underlying infection, suggests that although
CA-MRSA was significantly associated with endocarditis,
this may be more related to risk associated with intrave-
nous drug use and other outcomes such as mortality
may still not be as severe as among other endocarditis
patients [42,43]. Furthermore, other studies have sug-
gested that HIV infection was not significantly asso-
ciated with mortality among patients with infective
endocarditis in which 65% were caused by S. aureus,
38% of patients were HIV-positive and 16% mortality
was observed [6].
The retrospective nature of the study limited which
data were able to be collected and the availability of S.
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nition of USA300 MRSA to define CA-MRSA. While
USA300 remains the predominant CA-MRSA, we likely
underestimated the prevalence of CA-MRSA in this
study. Lastly, given the high prevalence of CA-MRSA,
ISU, and HIV in the study population and in Baltimore
City in general, the generalizability of these data to
other patient populations outside of urban, tertiary-care
settings should be performed with caution.
Conclusions
In conclusion, CA-MRSA was significantly associated
with an increased prevalence of endocarditis in this
cohort of HIV patients with MRSA bacteremia. Despite
that we observed lower mortality compared with other
studies, these patients remain at considerably higher risk
for the development of endocarditis and related mortal-
ity. In populations such as these, in which the preva-
lence of intravenous drug use and probability of
endocarditis are both high, efforts must be made for
early detection, which may improve treatment outcomes.
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